BR112023015520A2 - Transportador quimicamente acoplado para fármacos bioativos de baixa hidrofobicidade no sistema nervoso central - Google Patents
Transportador quimicamente acoplado para fármacos bioativos de baixa hidrofobicidade no sistema nervoso centralInfo
- Publication number
- BR112023015520A2 BR112023015520A2 BR112023015520A BR112023015520A BR112023015520A2 BR 112023015520 A2 BR112023015520 A2 BR 112023015520A2 BR 112023015520 A BR112023015520 A BR 112023015520A BR 112023015520 A BR112023015520 A BR 112023015520A BR 112023015520 A2 BR112023015520 A2 BR 112023015520A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- nervous system
- central nervous
- low hydrophobicity
- chemically coupled
- Prior art date
Links
- 230000000975 bioactive effect Effects 0.000 title abstract 4
- 210000003169 central nervous system Anatomy 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 102000012498 secondary active transmembrane transporter activity proteins Human genes 0.000 title 1
- 108040003878 secondary active transmembrane transporter activity proteins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000004770 neurodegeneration Effects 0.000 abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 3
- 239000004098 Tetracycline Substances 0.000 abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
- 229960002180 tetracycline Drugs 0.000 abstract 2
- 229930101283 tetracycline Natural products 0.000 abstract 2
- 235000019364 tetracycline Nutrition 0.000 abstract 2
- 150000003522 tetracyclines Chemical class 0.000 abstract 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical class C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 abstract 1
- 229960003638 dopamine Drugs 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
transportador quimicamente acoplado para fármacos bioativos de baixa hidrofobicidade no sistema nervoso central. a presente descrição provê um composto compreendendo um derivado de tetraciclina modificado, acoplado covalentemente através de um ligante definido pela fórmula genérica xzx a uma molécula bioativa de baixa hidrofobicidade útil para o tratamento de doenças neurodegenerativas, particularmente um composto em que o derivado de tetraciclina modificado é um derivado de doxiciclina quimicamente modificado e a molécula bioativa de baixa hidrofobicidade útil para o tratamento de doenças neurodegenerativas é dopamina. a descrição também provê um processo para preparar tal composto, bem como métodos para tratar uma doença neurodegenerativa compreendendo administrar o referido composto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163145190P | 2021-02-03 | 2021-02-03 | |
| PCT/IB2022/050920 WO2022167954A1 (en) | 2021-02-03 | 2022-02-02 | Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023015520A2 true BR112023015520A2 (pt) | 2023-10-24 |
Family
ID=80780479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023015520A BR112023015520A2 (pt) | 2021-02-03 | 2022-02-02 | Transportador quimicamente acoplado para fármacos bioativos de baixa hidrofobicidade no sistema nervoso central |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11951170B2 (pt) |
| EP (1) | EP4271415B1 (pt) |
| JP (1) | JP2024505700A (pt) |
| KR (1) | KR20230154834A (pt) |
| CN (1) | CN117597149A (pt) |
| AR (1) | AR127596A1 (pt) |
| AU (1) | AU2022215936A1 (pt) |
| BR (1) | BR112023015520A2 (pt) |
| CA (1) | CA3207324A1 (pt) |
| IL (1) | IL304921A (pt) |
| MX (1) | MX2023009105A (pt) |
| WO (1) | WO2022167954A1 (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939174A (en) * | 1988-02-26 | 1990-07-03 | Shashoua Victor E | Appetite suppression with dopamine-fatty acid conjugates |
| AU2002341970B2 (en) * | 2001-10-05 | 2008-02-14 | Tetragenex Pharmaceuticals, Inc. | Tetracycline derivatives and methods of use thereof |
| AU2003235759A1 (en) | 2002-01-08 | 2003-07-24 | Paratek Pharmaceuticals, Inc. | 4-dedimethylamino tetracycline compounds |
| EP1549323A2 (en) * | 2002-05-07 | 2005-07-06 | A & D Bioscience, Inc. | Conjugates comprising central nervous system active drug |
| WO2004064728A2 (en) * | 2003-01-16 | 2004-08-05 | Paratek Pharmaceuticals, Inc. | Use of specific tetracycline compounds in therapy |
| WO2020084168A1 (en) * | 2018-10-26 | 2020-04-30 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Tetracycline compound for treating drug-induced dyskinesia |
-
2022
- 2022-02-02 EP EP22710718.2A patent/EP4271415B1/en active Active
- 2022-02-02 JP JP2023547606A patent/JP2024505700A/ja active Pending
- 2022-02-02 KR KR1020237029848A patent/KR20230154834A/ko unknown
- 2022-02-02 AU AU2022215936A patent/AU2022215936A1/en active Pending
- 2022-02-02 AR ARP220100216A patent/AR127596A1/es unknown
- 2022-02-02 WO PCT/IB2022/050920 patent/WO2022167954A1/en active Application Filing
- 2022-02-02 MX MX2023009105A patent/MX2023009105A/es unknown
- 2022-02-02 IL IL304921A patent/IL304921A/en unknown
- 2022-02-02 CA CA3207324A patent/CA3207324A1/en active Pending
- 2022-02-02 CN CN202280026175.2A patent/CN117597149A/zh active Pending
- 2022-02-02 BR BR112023015520A patent/BR112023015520A2/pt unknown
-
2023
- 2023-03-14 US US18/121,318 patent/US11951170B2/en active Active
-
2024
- 2024-02-28 US US18/590,749 patent/US20240197892A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11951170B2 (en) | 2024-04-09 |
| CA3207324A1 (en) | 2022-08-11 |
| MX2023009105A (es) | 2023-11-17 |
| EP4271415B1 (en) | 2024-07-03 |
| EP4271415A1 (en) | 2023-11-08 |
| IL304921A (en) | 2023-10-01 |
| KR20230154834A (ko) | 2023-11-09 |
| WO2022167954A1 (en) | 2022-08-11 |
| US20230218768A1 (en) | 2023-07-13 |
| US20240197892A1 (en) | 2024-06-20 |
| AR127596A1 (es) | 2024-02-14 |
| AU2022215936A1 (en) | 2023-08-24 |
| CN117597149A (zh) | 2024-02-23 |
| JP2024505700A (ja) | 2024-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001739A1 (es) | Compuestos tricíclicos sustituidos | |
| BR112022000064A2 (pt) | Inibidores de hpk1 e usos dos mesmos | |
| ECSP18081153A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| CL2022001392A1 (es) | Compuestos tricíclicos sustituidos | |
| CL2020001343A1 (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| CU20110142A6 (es) | Procedimiento para tratar enfermedades inflamatorias o alérgicas | |
| CR10250A (es) | Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g | |
| CO6321277A2 (es) | Derivado heterociclico fusionado que tiene una actitud inhibidora de smo superior y baja toxicidad | |
| BR112013030894A2 (pt) | moduladores do sistema imune | |
| CR20160287A (es) | Inhibidores de syk | |
| BRPI0919868B8 (pt) | processo para a preparação de um derivado de clorina ou de bacterioclorina | |
| BR112014003079A2 (pt) | derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes | |
| BRPI0908421B8 (pt) | solução estável de um composto farmacêutico | |
| UY31803A (es) | Compuesto cristalino | |
| BR112022024120A2 (pt) | Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo | |
| BR112022020814A2 (pt) | Métodos para tratamento de síndrome de liberação de citocina | |
| BR112019009078A2 (pt) | processo para a purificação de pirazolpiridazinas, sal e composição agrícola | |
| BR112015004523A2 (pt) | compostos de tetraciclina | |
| BR112013021180A2 (pt) | derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a) | |
| BR112023012947A2 (pt) | Inibidores de lrrk2 | |
| AR071084A1 (es) | Metodo para la produccion de sucralosa | |
| BR112023015520A2 (pt) | Transportador quimicamente acoplado para fármacos bioativos de baixa hidrofobicidade no sistema nervoso central | |
| AR096526A1 (es) | Agentes citotóxicos para el tratamiento del cáncer | |
| BR112015029619A2 (pt) | derivados de 1,3-diaminociclopentano carboxamida | |
| AR094318A1 (es) | Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o enfermedad cognitivo, neurodegenerativo o neuronal |